Aptose Biosciences Inc. entered into an agreement with Hanmi Pharmaceuticals on November 18, 2025, for Hanmi to acquire all common shares for C$2.41 each, a 28% premium over the recent trading price. The transaction is subject to shareholder and court approvals and will lead to Aptose’s delisting from the TSX.